Compare BLDP & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLDP | AQST |
|---|---|---|
| Founded | 1979 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.5M | 521.0M |
| IPO Year | 2009 | 2007 |
| Metric | BLDP | AQST |
|---|---|---|
| Price | $2.37 | $4.00 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $2.24 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 2.7M | 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | $41.84 | $14.23 |
| Revenue Next Year | $14.68 | $58.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $1.00 | $2.20 |
| 52 Week High | $4.10 | $7.55 |
| Indicator | BLDP | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 46.10 |
| Support Level | $1.79 | $3.69 |
| Resistance Level | $2.92 | $4.46 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 64.49 | 21.09 |
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from Poland followed by United States, United Kingdom, and other countries.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.